World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
105
Citations
42639
World Ranking
6747
National Ranking
3563

Allan Lipton publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Allan Lipton sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 590 publications — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Allan Lipton D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Allan Lipton sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 105 D-Index — 67th percentile

67% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Allan Lipton is affiliated with the Penn State Milton S. Hershey Medical Center in the United States. Their research spans several areas within medicine, with a notable focus on oncology. The main field of study for Lipton is Medicine, with a significant number of publications in Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Cancer Research, and Molecular Biology.

Their work frequently addresses topics including Radiopharmaceutical Chemistry and Applications, Cancer Immunotherapy and Biomarkers, Bone Health and Treatments, Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, Global Cancer Incidence and Screening, and Prostate Cancer Treatment and Research.

Lipton has contributed to a variety of recent research articles, including:

  • Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval, 2022, Journal of bone oncology
  • Oncobiology and treatment of breast cancer in young women, 2022, Cancer and Metastasis Reviews
  • Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types, 2022, Cellular and Molecular Life Sciences
  • Diagnostic delays in breast cancer among young women: An emphasis on healthcare providers, 2023, The Breast
  • Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases, 2020, Cancers

Their frequent coauthors include Suhail M. Ali, Kim Leitzel, Luís Costa, Prashanth Moku, and Hyma Polimera.

Lipton publishes regularly in journals such as Journal of Clinical Oncology, Cancer Research, Journal of bone oncology, Cancer and Metastasis Reviews, and The Breast.

Best Publications

  • Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

    Alison T. Stopeck;Allan Lipton;Jean Jacques Body;Guenther G. Steger

  • Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

    Mark D. Pegram;Allen Lipton;Daniel F. Hayes;Barbara L. Weber

  • Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

    James R. Berenson;Alan Lichtenstein;Lester Porter;Meletios A. Dimopoulos

  • American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer

    Bruce E. Hillner;James N. Ingle;Rowan T. Chlebowski;Julie Gralow

  • Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases

    Gabriel N. Hortobagyi;Richard L. Theriault;Lester Porter;Douglas Blayney

  • Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.

    Allan Lipton;Richard L. Theriault;Gabriel N. Hortobagyi;Joseph Simeone

  • Platelets as a source of fibroblast growth-promoting activity.

    Nancy Kohler;A. Lipton

  • Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.

    James R. Berenson;Alan Lichtenstein;Lester Porter;Meletios A. Dimopoulos

  • Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

    Gabriel N. Hortobagyi;Richard L. Theriault;Allan Lipton;Lester Porter

  • Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial

    Richard L. Theriault;Allan Lipton;Gabriel N. Hortobagyi;Richard Leff

  • Pathologic fractures correlate with reduced survival in patients with malignant bone disease.

    Fred Saad;Allan Lipton;Richard Cook;Yin Miao Chen

  • A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.

    Jean Jacques Body;Thierry Facon;Robert E. Coleman;Allan Lipton

  • Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: A double-blind, randomized dose-response study

    James R. Berenson;Lee S. Rosen;Anthony Howell;Lester Porter

  • Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors

    Janet E. Brown;Richard J. Cook;Pierre Major;Pierre Major;Allan Lipton

  • Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid

    Robert E. Coleman;Pierre Major;Allan Lipton;Janet E. Brown

  • American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma

    James R. Berenson;Bruce E. Hillner;Robert A. Kyle;Ken Anderson

  • Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates

    Karim Fizazi;Allan Lipton;Xavier Mariette;Jean-Jacques Body

  • Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

    Allan Lipton;Karim Fizazi;Alison T. Stopeck;David H. Henry

  • Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel

    M. Aapro;P. A. Abrahamsson;J. J. Body;R. E. Coleman

  • American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer

    Bruce E. Hillner;James N. Ingle;James R. Berenson;Nora A. Janjan

Frequent Co-Authors

Robert E. Coleman
Robert E. Coleman University of Sheffield
Laurence M. Demers
Laurence M. Demers Pennsylvania State University
Richard J. Cook
Richard J. Cook University of Waterloo
Fred Saad
Fred Saad University of Montreal
Jean-Jacques Body
Jean-Jacques Body Université Libre de Bruxelles
Matthew R. Smith
Matthew R. Smith Harvard University
Karim Fizazi
Karim Fizazi University of Paris-Saclay
Vernon M. Chinchilli
Vernon M. Chinchilli Pennsylvania State University
Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Evangelos Terpos
Evangelos Terpos National and Kapodistrian University of Athens

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Medicine in the USA offers many rewarding career options beyond just the traditional MD. For those interested in patient care and healthcare leadership, nursing school online provides a flexible, accessible path. Online programs make it easier for working professionals or those balancing family commitments to advance their education.

Many registered nurses now seek higher qualifications to expand their clinical and leadership roles. Completing an rn to bsn online is a popular choice, providing upgraded skills and better job prospects. Those targeting advanced practice or research roles may consider an online phd in nursing, opening doors in teaching, policy, and advanced clinical work.

Not a nurse yet? Direct-entry programs are designed for those from non-nursing backgrounds. The direct entry np programs for non nurses online let career changers enter the nurse practitioner field through intensive, accelerated study.

Best Scientists Citing Allan Lipton

Trending Scientists

Recently Published Articles